WealthOne’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

WealthOne’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12	Closed	–	–	609
2018 Q4	$0	Buy	+12	New	+$20	﹤0.01%	604

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

WealthOne's CTIC Position: Q1 2019 in Review

WealthOne sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2019, closing a stake of 12 shares.

WealthOne first reported a position in CTIC in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 67 funds tracked by Wall St. Rank hold CTIC as of Q1 2019.

WealthOne reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2019 after selling out during the quarter.
WealthOne sold 12 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2019.
WealthOne first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2018 and held it in 1 quarter.
WealthOne's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q4 2018.
67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2019.

Based on WealthOne's 13F filing for Q1 2019, filed 16 May 2019.